Know Labs Inc. (OTCMKTS:KNWN) Offers Video Update Regarding IRB-Approved Internal Trial

Know Labs Inc. (OTCMKTS:KNWN) shared a video update on September 02, 2022, about the IRB-approved internal trial that it had been conducting at its laboratory in Seattle. This clinical trial was announced in a press release earlier in 2022.

Trading Data

On Friday, KNWN stock lost 1.98% to $2.2300 with 33.20K shares, compared to its average volume 52.91K shares. The stock moved within a range of $2.1200 – 2.3500 after opening trade at $2.2675.

Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology

The video, which is a couple of minutes long, talks about the trial process, while Know Labs’ Chief Product Officer, Steve Kent explains the protocol for the internal clinical trial and reviews its primary goal. The sole objective of the trial is to further fine-tune the algorithm that controls and enables Bio-RFID to identify and measure glucose in the body accurately.

Steve Kent says that the clinical team collects thousands of data points each time the test is performed. After validating the data, Know Labs data scientists, use complex methodologies to improve the algorithm’s accuracy and stability. They are taking every step to ensure it is done right and creating a production-ready algorithm for the clinical trials that will be used in the application to the FDA. The Know Labs team’s focus remains on delivering the first FDA-cleared non-invasive blood glucose monitoring device.

Key Quote

“Our clinical team collects thousands of data points each time the test is performed. Once the data is validated, Know Labs data scientists apply complex methodologies to improve the algorithm’s accuracy and stability,” said Steve Kent. “It is a lot of work, but we are taking every step to ensure we get this right and create a production-ready algorithm for the clinical trials we will use in the application to the FDA.”

Technical Data

KNWN stock is trading above the 20-Day and 50-Day Moving averages of $2.20 and $2.20 respectively. Moreover, the stock is trading above the 200-Day moving average of $1.89.